About Swift Biosciences
Swift Biosciences is a Healthcare company based in Ann Arbor (United States) founded in 2010, and was acquired by Integrated DNA Technologies in March 2021. It develops and sells reagents for genetic testing and Next Generation Sequencing (NGS). Swift Biosciences has raised $35.2 million across 10 funding rounds from investors including Integrated DNA Technologies, Fletcher Spaght and Arboretum Ventures. The company has 41 employees. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is SWIFT BIOSCIENCES, INC. Its competitors include Neogen, GenScript and RareCyte; 3 of its 3 listed competitors have raised funding.
Company details
Swift Biosciences was founded in 2010 and is based in Ann Arbor, United States. Technologies for sample and library preparation in next-generation sequencing are developed by the company within the biotechnology sector. Products such as Accel-NGS DNA library kits for Illumina and Ion Torrent platforms, Accel-Amplicon Panels for mutation screening, and myT Primers for qPCR-based cancer detection are offered to support genetic testing operations.
- Headquarters Ann Arbor, United States
- Employees 41
- Stage Acquired
- SectorsHealthcare
- Website swiftbiosci.com
- Social LinkedIn X Facebook
- Acquired by Integrated DNA Technologies (Mar 2021)
- Legal Name Swift Biosciences, Inc.
- Total Equity Funding$35.2M (USD)
in 10 rounds
- Latest Funding Round$4M (USD), Series D
Nov 2018
- InvestorsIntegrated DNA Technologies
& 5 more
- Employee Count41
- Acquired byIntegrated DNA Technologies
(Mar 2021)
Funding Insights of Swift Biosciences
Swift Biosciences has successfully raised a total of $35.2M across 10 strategic funding rounds. The most recent funding activity was a Series D round of $4 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.2M
- Total Rounds 10
- Last Round Series D — $4M
- Investors Count 5
All 10 funding rounds of Swift Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $4M | Series D | – | – | – |
| Jun 2017 | $12.24M | Series D | – | Arboretum Ventures | – |
| Jan 2017 | $2.91M | Series C | – | – | – |
| Apr 2016 | $3.3M | Series C | – | – | – |
| Sep 2015 | $1.5M | Series C | – | – | – |
| Oct 2013 | $7M | Series B | – | Fletcher Spaght | |
| Jan 2013 | $750,000 | Series A | – | Charter Capital Partners | – |
| Feb 2012 | $500,000 | Series A | – | – | – |
| Aug 2010 | $3M | Series A | – | – | |
| Jan 2010 | Seed | – | – | – |
6 investors in total: 6 institutional.
Investors in Swift Biosciences
Swift Biosciences has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Integrated DNA Technologies, Fletcher Spaght and Arboretum Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare venture capital investments are made by Arboretum Ventures. | arboretumvc.com | Ann Arbor, United States | ||
Early-stage investments are directed toward US, India, and Canada firms. | mercuryfund.com | Houston, United States | ||
Management consulting and business management services are provided. | 1983 | fletcherspaght.com | Boston, United States | |
Operates as a fund of funds in the venture capital sector. | 2002 | renvcf.com | Ann Arbor, United States | |
Charter Capital Partners is engaged in M&A advisory and investment solutions. | 1989 | chartercapitalpartners.com | Grand Rapids, United States | |
Provider of oligonucleotide-based reagents and kits | 1987 | idtdna.com | Coralville, United States |
Investor details for Swift Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Swift Biosciences
298 people are tracked at Swift Biosciences (68 in leadership, 230 in team); the tracked headcount is 41.
| Name | Role | Group |
|---|---|---|
Gina Anderson | Head Of Sales, Clinical Solutions | Leadership |
Johnny Flowers | Director Of Software, Archer Products | Leadership |
Mark Behlke | Chief Scientific Officer | Leadership |
Linda De Jesus | VP & GM, Global Head of Commercial | Leadership |
Daniel Cerne | Director Of Engineering Technology Sustainment | Leadership |
Demaris Mills | President | Leadership |
Liz Chen | General Manager, IDT China | Leadership |
Hanna Dust | VP, Human Resources | Leadership |
Steve Wowk | VP, Business Unit and General Management | Leadership |
Grace Mangialardi | Vice President, Global Commercial Excellence | Leadership |
Adam Clore | Director Of Technology R&d | Leadership |
Verity Johnson | Vice President, Gene Reading Solutions | Leadership |
Mike Marvin | Director Of Small Molecule Chemistry | Leadership |
Stephan Starick | Sales Director | Leadership |
Casey Carpenter | Sr. Director, Digital Commerce Technologies | Leadership |
Loren Schoch | Senior Director, Therapeutics Commercialization | Leadership |
Erik Swenson | Chief Financial Officer | Leadership |
Bryan N. Höglund | Director Of Innovation Product Management | Leadership |
Mike Ashley | Vice President, Research And Development | Leadership |
Tanya B. | Director Of Marketing Communications And Brand | Leadership |
278 more people are available in the full profile.
Complete people profiles for Swift Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Swift Biosciences
4 dated milestones of Swift Biosciences across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Swift Biosciences is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $4.0M.
- Exit Acquired by Integrated DNA Technologies.
Competitors of Swift Biosciences
Swift Biosciences has 3 listed competitors in our database, 3 of them funded. They include Neogen, GenScript and RareCyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neogen.com | 1982 | Lansing, United States | $700,000 | 2,640 | Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood |
Detailed competitors of Swift Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Swift Biosciences
Websites that share an audience with Swift Biosciences (swiftbiosci.com).
Websites whose visitors overlap most with Swift Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
genecraft.de | genecraft.de | 100% | – | ||
| microzone.co.uk | 100% | #5,578,289 | View details | ||
| hylabs.co.il | 100% | #1,633,801 | View details | ||
highveld.com | highveld.com | 100% | – | ||
| taq-dna.com | 99% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Swift Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Swift Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Swift Biosciences
Complete news archive for Swift Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Swift Biosciences
Swift Biosciences was founded in 2010.
Swift Biosciences is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Swift Biosciences is a funded company, having raised a total of $35.2M across 10 funding rounds to date.
Swift Biosciences has 41 employees.
Swift Biosciences was founded in 2010 and is based in Ann Arbor, United States. Technologies for sample and library preparation in next-generation sequencing are developed by the company within the biotechnology sector. Products such as Accel-NGS DNA library kits for Illumina and Ion Torrent platforms, Accel-Amplicon Panels for mutation screening, and myT Primers for qPCR-based cancer detection are offered to support genetic testing operations.
Swift Biosciences has 6 investors. Key investors include Integrated DNA Technologies, Fletcher Spaght, Arboretum Ventures, Renaissance Venture Capital Fund, and Mercury Fund.
Swift Biosciences operates through Swift Biosciences, Inc..
Yes. Swift Biosciences was acquired by Integrated DNA Technologies in March 2021.